Myelodysplastic syndrome in an infant with constitutional pure duplication 1q41-qter

Hirokazu Morokawa1, Motoko Kamiya1,2, Keiko Waku2,3, Mikiko Kobayashi4, Takashi Kurata1, Kazuyuki Matsuda5, Rie Kawamura2,3, Hiroyuki Kanno4, Yoshimitsu Fukushima2,3, Yozo Nakazawa1 and Tomoki Kosho2,3

Abstract
We report on a Japanese female infant as the fourth patient with the constitutional pure duplication 1q41-qter confirmed by chromosomal microarray and as the first who developed myelodysplastic syndrome (MDS) among those with the constitutional 1q duplication. Common clinical features of the constitutional pure duplication 1q41-qter include developmental delay, craniofacial characteristics, foot malformation, hypertrichosis, and respiratory insufficiency. The association between MDS and the duplication of the genes in the 1q41-qter region remains unknown.

The constitutional pure duplication 1q41-qter is a condition with an excess of the 1q41-qter region but without imbalances of other chromosomal regions, associated with chromosomal rearrangements1–3. In only three among eight non-mosaic cases of pure duplication 1q41-qter published to date, imbalances of other chromosomal regions were excluded through molecular cytogenetic techniques, including chromosomal microarray (Table 1)2, 3. We report the fourth case of constitutional pure duplication 1q41-qter confirmed by chromosomal microarray and the first patient with a constitutional 1q duplication who developed myelodysplastic syndrome (MDS).

The proband was a girl, born as the first child of healthy nonconsanguineous Japanese parents. She was delivered by cesarean section at 37 weeks and 0 days of gestation after an uneventful pregnancy. Her birth weight was 2444 g (−0.3 SD), length 46.0 cm (−0.6 SD), and occipitofrontal circumference 34.5 cm (+1.4 SD). Apgar scores were 4 at 1 min and 7 at 5 min. She developed respiratory distress and received mechanical ventilation for 2 days, followed by oxygen supplementation for 3 months. Her physical findings at age 1 month included craniofacial features (macrocephaly, a large and prominent forehead, epicanthic folds, hypertelorism, a depressed nasal bridge, a high and narrow palate, retro/micrognathia), hypertrichosis, widely spaced nipples, a right single palmar crease, and syndactyly of the first to third toes of both feet. Brain, cardiac, and abdominal ultrasonography showed no abnormalities.

At age 1 month, her white blood cell count was 11.2 × 10^3/µL with leukemic blasts of 6.0% (Fig. 1a). The hemoglobin level was 7.1 g/dL, and the platelet count was 55 × 10^3/µL. She was transferred to our hospital. The initial bone marrow aspiration was performed at age 6 weeks. The smear showed blast cells (Fig. 1b). The clot section showed age-appropriate hypercellular marrow (Fig. 1c). Megakaryocytes were increased in number, and many of them displayed dysplasia, such as abnormally separated nuclear lobes (Fig. 1c, d). Erythroblasts exhibited diffuse distribution, and no apparent erythroblastoid islands were found (Fig. 1d). Immunohistochemical examination revealed CD41-positive micromegakaryocytes and small megakaryocytes (Fig. 1e). The follow-up bone marrow aspiration was performed at the age of 3 months. The clot histology showed a mild
| Reference            | Shin et al. [2] | Watanabe et al. [3] | Present patient |
|----------------------|-----------------|---------------------|-----------------|
| **Age at examination/sex** | 6 mo/M          | 1 y                | 1 y 7 mo/F      |
| **Cytogenetic analysis** | G-band, FISH, CMA | G-band, CMA       | G-band, FISH, CMA |
| **G-banded karyotype** | 46,XY,der(11)t(1;11) (q41; p15.5) | 46,XY,der(15)t(1;15) (q41; p?) | 46,XY,der(15)t(1;15) (q41;p11.2) |
| **Duplication size (Mb)** | 26.8            | 32.6               | 26.7            |
| **Origin** | Mat             | De novo            |                 |
| **Birth information** |                 |                     |                 |
| **Gestational weeks** | 39              | 37                 | 37              |
| **Weight (g)** | 2820            | 2444               | 2444            |
| **OFC (cm)** | 34.5            | 34.5               |                 |
| **Postnatal growth impairment** | +               | +                  | −               |
| **Developmental delay** | +               | +                  | +               |
| **Intellectual disability** | +              | +                  | +               |
| **Craniofacial features** |                 |                     |                 |
| **Macrocephaly** | +               | +                  | −               |
| **Large fontanels** | −               | −                  | −               |
| **Prominent forehead** | +              | +                  | +               |
| **Widely spaced sutures** | +             |                     |                 |
| **Epicantih folds** | +               |                     | +               |
| **Hypertelorism** | +               | −                  | −               |
| **Triangle face** | +               | −                  | +               |
| **Downslanting palpebral fissures** | +           | −                  | +               |
| **Broad nasal bridge** | +             | +                  | +               |
| **High palate** | −               | −                  | −               |
| **Micro/retrognathia** | +             | +                  | +               |
| **Low-set ears** | +               | +                  | +               |
| **Short neck** | +               |                     | +               |
| **Widely spaced nipples** | +            |                     |                 |
| **Hand/foot malformation** | −              | + (Overlapping toes) | + (Syndactyly) |
| **Hypertrichosis** | +               |                     | +               |
| **CNS abnormalities** | −               | + (Ventricular dilatation) | −               |
| **Cardiac malformations** | −            | −                  | −               |
| **Urogenital anomalies** | −             | +                  | −               |
| **Respiratory insufficiency** | −           | + (Recurrent infection) | +               |
| **Gastrointestinal abnormalities** | −          | −                  | −               |
| **Others** | MDS            |                     |                 |

CMA chromosomal microarray, CNS central nervous system, F female, M male, Mat maternal, MDS myelodysplastic syndrome, mo month(s), OFC occipitofrontal circumference, y year(s)
increase in blast cells in addition to the findings in the initial examination (data not shown). Immunohistochemistry showed scattered p53-positive cells and slightly increased CD34-positive blasts. There was fetal hemoglobin expression in some erythroblasts and an increase in CD42b-positive megakaryocytes, which were small and mononuclear (data not shown).

G-banded karyotyping of the bone marrow cells to detect the chromosomal abnormalities responsible for hematological malignancy showed 46,XX,add(7)(p22) at age 6 weeks. This chromosomal aberration was thought to be constitutional. G-banding of phytohemagglutinin-stimulated peripheral blood was performed at age 2 months when the peripheral blood blasts decreased to 2.0%, and the karyotype showed the same abnormalities on chromosome 7 (Fig. 1f). Parental karyotypes were normal. The follow-up G-banding of the bone marrow cells at age 9 months showed trisomy 8 as an additional chromosomal aberration in 5/22 (22.7%) cells with 2.0% blasts.

The peripheral blood showed a persistently low level of monocyes (>1 × 10^9/L was not maintained), hemoglobin (<10 g/dL), and platelet (<10 × 10^4/µL). Leukemic blasts were detected in 2–4% of the bone marrow cells and in 3–9% (1–2 months of age) and ~3% (~3 months of age) of the peripheral blood cells. Auer rods were not found in the peripheral blood smear or bone marrow smear. In view of all these hematological findings as well as the exclusion of infectious diseases, metabolic disorders, or other causes of cytopenia or dysplasia, she was diagnosed with refractory anemia with excess blasts-1 (RAEB-1) according to the 2008 revision of the World Health Organization (WHO) classification and with MDS with additional trisomy 1q remains unknown. It is thought to be constitutional (52%) were found to have clonal chromosomal aberrations, identified with trisomy 1q as the second most frequent (20%) and with or without additional karyotypic abnormalities, recognized as a distinct entity named 5q− syndrome according to the WHO classification. Clonal chromosomal abnormalities are detected in approximately 50% of patients of primary MDS. The most frequent abnormalities are interstitial deletions of the long arm of chromosome 5 (del(5q) or 5q−) with or without additional karyotypic abnormalities, recognized as a distinct entity named 5q− syndrome according to the WHO classification. A large database from Austria, in which 1080 among 2072 patients with MDS (52%) were found to have clonal chromosomal abnormalities, identified deletions of 5q (30% of the 1080 patients), −7 del(7q) (21%), +8 (16%), −18/18q− (7%), 20q− (6%), −Y (5%), −17/17p− (including isochromosome (17q)) (5%), +Mar (5%), +21 (4%), inv/t(3q) (4%), −13/13q− (4%), +t(1q)+ (3%), −21 (3%), +11 (3%), 12p−(2%), t(5q) (2%), 11q− (2%), and t(7q) (2%)7. Interestingly, a multicenter study from Korea, in which 92 among 205 patients (45%) were found to have clonal chromosomal abnormalities, identified trisomy 1q as the second most frequent chromosomal abnormality (15%), with trisomy 8 as the most frequent (20%)6. The pathogenesis of MDS associated with clonal trisomy 1q remains unknown. It is usually present with additional common abnormalities such as trisomy 8, monosomy 5, or monosomy 7, suggesting that 1q abnormalities are mostly secondary events.

We used a whole-genome oligonucleotide based-array platform consisting of 180K oligonucleotides (CGXTM SNP v1.1; PerkinElmer Inc., Waltham, MA). The data were analyzed with Genoglyphix software (PerkinElmer Inc.) according to the human genome assembly Feb 2009 (GRCh 37/hg19). A 26.74 Mb gain was shown in the 1q41-pter region (Fig. 1f), with an average log2 ratio of 0.527, compatible with the full trisomy state in this region. No copy number loss was detected in the 7p22.3-pter region with microarray using our platform (Fig. 1f).

Clonal chromosomal abnormalities are detected in approximately 50% of patients of primary MDS. The most frequent abnormalities are interstitial deletions of the long arm of chromosome 5 (del(5q) or 5q−) with or without additional karyotypic abnormalities, recognized as a distinct entity named 5q− syndrome according to the WHO classification. A large database from Austria, in which 1080 among 2072 patients with MDS (52%) were found to have clonal chromosomal abnormalities, identified deletions of 5q (30% of the 1080 patients), −7 del(7q) (21%), +8 (16%), −18/18q− (7%), 20q− (6%), −Y (5%), −17/17p− (including isochromosome (17q)) (5%), +Mar (5%), +21 (4%), inv/t(3q) (4%), −13/13q− (4%), +t(1q)+ (3%), −21 (3%), +11 (3%), 12p−(2%), t(5q) (2%), 11q− (2%), and t(7q) (2%)7. Interestingly, a multicenter study from Korea, in which 92 among 205 patients (45%) were found to have clonal chromosomal abnormalities, identified trisomy 1q as the second most frequent chromosomal abnormality (15%), with trisomy 8 as the most frequent (20%)6. The pathogenesis of MDS associated with clonal trisomy 1q remains unknown. It is usually present with additional common abnormalities such as trisomy 8, monosomy 5, or monosomy 7, suggesting that 1q abnormalities are mostly secondary events.
Fig. 1 (See legend on next page.)
representing clonal evolution. Contrarily, the involvement of 1q heterochromatin associated with unbalanced centromeric translocation was found as the primary clonal abnormality in several patients with MDS, which suggested the importance of 1q heterochromatin in the development of MDS. A 26.74-Mb gain in the 1q41-qter region shown in the proband included 95 genes listed in Online Mendelian Inheritance in Man (Supplementary Table 1). Among the 95 genes, PARP1, AKT3, and TP53BP2 are known as oncogenes, though they have not been reported to be associated with the development of MDS. The abnormal expression of these genes related to oncogenesis has been reported in various human tumors, including hematopoietic malignancies. However, there have been no reports of patients with constitutional 1q duplication who developed MDS or other hematological malignancies. Therefore, MDS in the proband might be a coincidental event and may be associated with other genetic and/or environmental factor(s).

In conclusion, we describe the detailed hematological and molecular cytogenetic findings of the fourth patient with the constitutional pure duplication 1q41-qter and the first who developed MDS among those with the constitutional 1q duplication. Common clinical features in constitutional pure duplication 1q41-qter include developmental delay, craniofacial characteristics, foot malformation, hypertrichosis, and respiratory insufficiency. The association between MDS and duplicated genes in the 1q41-qter region in the proband remains unknown.

HGV Database
The relevant data from this Data Report are hosted at the Human Genome Variation Database at http://dx.doi.org/10.6084/m9.figshare.hgv.1949, http://dx.doi.org/10.6084/m9.figshare.hgv.1952, http://dx.doi.org/10.6084/m9.figshare.hgv.1958, http://dx.doi.org/10.6084/m9.figshare.hgv.1961, http://dx.doi.org/10.6084/m9.figshare.hgv.1964, http://dx.doi.org/10.6084/m9.figshare.hgv.1967, http://dx.doi.org/10.6084/m9.figshare.hgv.1970, http://dx.doi.org/10.6084/m9.figshare.hgv.1973, http://dx.doi.org/10.6084/m9.figshare.hgv.1976, http://dx.doi.org/10.6084/m9.figshare.hgv.1979, http://dx.doi.org/10.6084/m9.figshare.hgv.1982, http://dx.doi.org/10.6084/m9.figshare.hgv.1985, http://dx.doi.org/10.6084/m9.figshare.hgv.1994, http://dx.doi.org/10.6084/m9.figshare.hgv.1997, http://dx.doi.org/10.6084/m9.figshare.hgv.2000, http://dx.doi.org/10.6084/m9.figshare.hgv.2003, http://dx.doi.org/10.6084/m9.figshare.hgv.2006, http://dx.doi.org/10.6084/m9.figshare.hgv.2009, http://dx.doi.org/10.6084/m9.figshare.hgv.2012, http://dx.doi.org/10.6084/m9.figshare.hgv.2015, http://dx.doi.org/10.6084/m9.figshare.hgv.2018, http://dx.doi.org/10.6084/m9.figshare.hgv.2021, http://dx.doi.org/10.6084/m9.figshare.hgv.2024, http://dx.doi.org/10.6084/m9.figshare.hgv.2027, http://dx.doi.org/10.6084/m9.figshare.hgv.2030, http://dx.doi.org/10.6084/m9.figshare.hgv.2033, http://dx.doi.org/10.6084/m9.figshare.hgv.2039, http://dx.doi.org/10.6084/m9.figshare.hgv.2042, http://dx.doi.org/10.6084/m9.figshare.hgv.2045, http://dx.doi.org/10.6084/m9.figshare.hgv.2048, http://dx.doi.org/10.6084/m9.figshare.hgv.2051, http://dx.doi.org/10.6084/m9.figshare.hgv.2057, http://dx.doi.org/10.6084/m9.figshare.hgv.2066, http://dx.doi.org/10.6084/m9.figshare.hgv.2069, http://dx.doi.org/10.6084/m9.figshare.hgv.2072, http://dx.doi.org/10.6084/m9.figshare.hgv.2075, http://dx.doi.org/10.6084/m9.figshare.hgv.2078, http://dx.doi.org/10.6084/m9.figshare.hgv.2081, http://dx.doi.org/10.6084/m9.figshare.hgv.2084, http://dx.doi.org/10.6084/m9.figshare.hgv.2087, http://dx.doi.org/10.6084/m9.figshare.hgv.2090, http://dx.doi.org/10.6084/m9.figshare.hgv.2093, http://dx.doi.org/10.6084/m9.figshare.hgv.2096, http://dx.doi.org/10.6084/m9.figshare.hgv.2099, http://dx.doi.org/10.6084/m9.figshare.hgv.2102, http://dx.doi.org/10.6084/m9.figshare.hgv.2105, http://dx.doi.org/10.6084/m9.figshare.hgv.2108, http://dx.doi.org/10.6084/m9.figshare.hgv.2111, http://dx.doi.org/10.6084/m9.figshare.hgv.2114, http://dx.doi.org/10.6084/m9.figshare.hgv.2117, http://dx.doi.org/10.6084/m9.figshare.hgv.2120, http://dx.doi.org/10.6084/m9.figshare.hgv.2123, http://dx.doi.org/10.6084/m9.figshare.hgv.2126, http://dx.doi.org/10.6084/m9.figshare.hgv.2130, http://dx.doi.org/10.6084/m9.figshare.hgv.2138, http://dx.doi.org/10.6084/m9.figshare.hgv.2141, http://dx.doi.org/10.6084/m9.figshare.hgv.2144, http://dx.doi.org/10.6084/m9.figshare.hgv.2147, http://dx.doi.org/10.6084/m9.figshare.hgv.2150, http://dx.doi.org/10.6084/m9.figshare.hgv.2153, http://dx.doi.org/10.6084/m9.figshare.hgv.2159, http://dx.doi.org/10.6084/m9.figshare.hgv.2162, http://dx.doi.org/10.6084/m9.figshare.hgv.2165, http://dx.doi.org/10.6084/m9.figshare.hgv.2168, http://dx.doi.org/10.6084/m9.figshare.hgv.2171, http://dx.doi.org/10.6084/m9.figshare.hgv.2174, http://dx.doi.org/10.6084/m9.figshare.hgv.2177, http://dx.doi.org/10.6084/m9.figshare.hgv.2183, http://dx.doi.org/10.6084/m9.figshare.hgv.2186, http://dx.doi.org/10.6084/m9.figshare.hgv.2189, http://dx.doi.org/10.6084/m9.figshare.hgv.2192, http://dx.doi.org/10.6084/m9.figshare.hgv.2195, http://dx.doi.org/10.6084/m9.figshare.hgv.2198, http://dx.doi.org/10.6084/m9.figshare.hgv.2201, http://dx.doi.org/10.6084/m9.figshare.hgv.2204, http://dx.doi.org/10.6084/m9.figshare.hgv.2207, http://dx.doi.org/10.6084/m9.figshare.hgv.2210, http://dx.doi.org/10.6084/m9.figshare.hgv.2213, http://dx.doi.org/10.6084/m9.figshare.hgv.2216, http://dx.doi.org/10.6084/m9.figshare.hgv.2219, http://dx.doi.org/10.6084/m9.figshare.hgv.2222, http://dx.doi.org/10.6084/m9.figshare.hgv.2225, http://dx.doi.org/10.6084/m9.figshare.hgv.2228, http://dx.doi.org/10.6084/m9.figshare.hgv.2231, http://dx.doi.org/10.6084/m9.figshare.hgv.2234, http://dx.doi.org/10.6084/m9.figshare.hgv.2237, http://dx.doi.org/10.6084/m9.figshare.hgv.2240, http://dx.doi.org/10.6084/m9.figshare.hgv.2243, http://dx.doi.org/10.6084/m9.figshare.hgv.2246, http://dx.doi.org/10.6084/m9.figshare.hgv.2249, http://dx.doi.org/10.6084/m9.figshare.hgv.2252, http://dx.doi.org/10.6084/m9.figshare.hgv.2255.
Acknowledgements

We are grateful to all of the medical staff involved in this study, as well as the central review board members in the MDS committee of the Japan Society of Hematology/Oncology. We also thank Ellen Knapp from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. This work was supported by the Program for the Integrated Database of Clinical and Genomic Information from the Japan Agency for Medical Research and Development and Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare, Japan.

Author details

1Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan. 2Center for Medical Genetics, Shinshu University Hospital, Matsumoto, Japan. 3Department of Medical Genetics, Shinshu University Hospital, Matsumoto, Japan. 4Department of Pathology, Shinshu University School of Medicine, Matsumoto, Japan. 5Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

is available for this paper at https://doi.org/10.1038/s41439-018-0008-8.

Received: 7 January 2018 Revised: 25 March 2018 Accepted: 30 March 2018 Published online: 21 May 2018

References

1. Kulikowski, L. D. et al. Pure duplication 1q41-qter: further delineation on trisomy 1q syndromes. Am. J. Med. Genet. A 164A, 2663–2667 (2008).
2. Shin, Y. B. et al. Partial trisomy 1q41 syndrome delineated by whole genomic array comparative genome hybridization. J. Korean Med. Sci. 23, 1097–1101 (2008).
3. Watanabe, S. et al. Detailed analysis of 26 cases of 1q partial duplication/triplication syndrome. Am. J. Med. Genet. A 170A, 908–917 (2016).
4. Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937–951 (2009).
5. Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405 (2016).
6. Shimizu, K. et al. Microarray and FISH-based genotype-phenotype analysis of 22 Japanese patients with Wolf-Hirschhorn syndrome. Am. J. Med. Genet. A 164A, 597–609 (2014).
7. Hase, D. et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110, 4385–4395 (2007).
8. Lee, D. S. et al. Predominance of trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study. Cancer Genet. Cytogenet. 132, 97–101 (2001).
9. Willington, K., Hundraill, S. D., Northup, J., Panova, N. & Velagaleti, G. Role of chromosome 1 pericentric heterochromatin (1q) in pathogenesis of myelodysplastic syndrome: report of 2 new cases. Exp. Mol. Pathol. 84, 189–193 (2008).
10. O dhe, O. F. F. et al. Recurrent unbalanced whole arm t(1;10)(q10;p10) in myelodysplastic syndrome: a case report and literature review. Cancer Genet. Cytogenet. 172, 165–167 (2007).
11. Hafner, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241–247 (2014).
12. Makishima, H. et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat. Genet. 49, 204–212 (2017).
13. Wang, L. et al. Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene. Oncotarget 6, 27460–27474 (2015).
14. Bellosa, C., Kumar, C. C., Di Cristofano, A. & Testa, J. R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 94, 29–86 (2005).
15. Mais, G. I. et al. Specific plasma autoantibody reactivity in myelodysplastic syndrome. Sci. Rep. 3, 3311 (2013).
16. Wang, Z. et al. N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence. Proc. Natl. Acad. Sci. USA 110, 312–317 (2013).